Vyepti^®

(Eptinezumab) ^6-7 Lundbeck

• Eptinezumab is a recombinant humanized monoclonal antibody that selectively inhibits calcitonin generelated peptide (CGRP)

Composition:

• Available as a 100 mg/1mL concentrated solution for infusion

Indications:

Newly indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month

References:

6. Vyepti (Eptinezumab). Abbreviated Prescribing Information.

7. BarbantiP, GoadsbyPJ, LambruG, et al. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. J Headache Pain. 2022;23(1):153. doi:10.1186/s10194-022-01521-w